Literature DB >> 12370404

A transgenic mouse model of autoimmune glomerulonephritis and necrotizing arteritis associated with cryoglobulinemia.

Shuichi Kikuchi1, Yves Pastore, Liliane Fossati-Jimack, Aki Kuroki, Haruyoshi Yoshida, Thierry Fulpius, Kimi Araki, Satoru Takahashi, Robert Lemoine, Luc Reininger, Shozo Izui.   

Abstract

Mice implanted with hybridoma secreting 6-19 IgG3 anti-IgG2a rheumatoid factor (RF) with cryoglobulin activity develop acute glomerulonephritis and cutaneous leukocytoclastic vasculitis. As the RF activity is implicated in the skin, but not glomerular lesions, it is still unclear whether the renal pathogenicity is determined by 6-19 H chains alone or their combination with L chains. To address this question, we have generated transgenic mice expressing only the H chain gene or both H and L chain genes of the 6-19 IgG3 anti-IgG2a RF and determined the development of glomerular and vascular lesions. H-single and H/L-double transgenic mice displayed comparable high amounts of IgG3 cryoglobulins, but only H/L-double transgenic mice having 10-fold higher levels of IgG3 anti-IgG2a RF progressively developed chronic, lethal glomerulonephritis. The severe glomerular lesions observed at 8-10 mo of age were very heterogeneous (membranoproliferative changes, crescents, and sclerosis); in addition, one-third of them had necrotizing arteritis in the kidneys and skeletal muscles. These renal and vascular changes were very different from those observed in the acute cryoglobulinemia, characterized by mainly "wire-loop" glomerular lesions and a cutaneous leukocytoclastic form of vasculitis. Thus, our data demonstrate the importance of a unique combination of the H and L chains for the expression of the pathogenic activity of IgG3 cryoglobulins and that a single autoantibody is able to induce different types of glomerular and vascular complications, depending on its production levels and kinetics.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12370404     DOI: 10.4049/jimmunol.169.8.4644

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  Protease nexin-1, tPA, and PAI-1 are upregulated in cryoglobulinemic membranoproliferative glomerulonephritis.

Authors:  Sekiko Taneda; Kelly L Hudkins; Anja S Mühlfeld; Jolanta Kowalewska; Jeffrey W Pippin; Stuart J Shankland; Charles E Alpers
Journal:  J Am Soc Nephrol       Date:  2008-01-16       Impact factor: 10.121

2.  Animal models of vasculitides.

Authors:  Uriel Katz; Boris Gilburd; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2008-10       Impact factor: 8.667

3.  A case of rapid amelioration of hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis treated by interferon-free directly acting antivirals for HCV in the absence of immunosuppressant.

Authors:  Fumiaki Obata; Taichi Murakami; Junko Miyagi; Sayo Ueda; Taizo Inagaki; Masanori Minato; Hiroyuki Ono; Kenji Nishimura; Eriko Shibata; Masanori Tamaki; Sakiya Yoshimoto; Fumi Kishi; Seiji Kishi; Motokazu Matsuura; Kojiro Nagai; Hideharu Abe; Toshio Doi
Journal:  CEN Case Rep       Date:  2016-11-21

4.  Sialylation determines the nephritogenicity of IgG3 cryoglobulins.

Authors:  Masako Otani; Aki Kuroki; Shuichi Kikuchi; Masao Kihara; Junichiro Nakata; Kiyoaki Ito; Jun-ichi Furukawa; Yasuro Shinohara; Shozo Izui
Journal:  J Am Soc Nephrol       Date:  2012-09-27       Impact factor: 10.121

Review 5.  Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies.

Authors:  Lucie Baudino; Samareh Azeredo da Silveira; Munehiro Nakata; Shozo Izui
Journal:  Springer Semin Immunopathol       Date:  2006-09-05

Review 6.  Diagnostics and treatment of cryoglobulinaemia: it takes two to tango.

Authors:  Jan Damoiseaux; Jan Willem Cohen Tervaert
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

Review 7.  Hepatitis Virus C-associated Nephropathy: A Review and Update.

Authors:  Elmukhtar Habas; Khalifa L Farfar; Nada Errayes; Ala M Habas; Mehdi Errayes; Gamal Alfitori; Amnna Rayani; Mohamed Elgara; Aisha H Al Adab; Abdulnaser Elzouki
Journal:  Cureus       Date:  2022-07-27
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.